Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757054 | 0.83 | TSHR (0.39) | TSHRALDH1A1SMN1; SMN2DNM1 | |
| SCHEMBL5165999 | 0.83 | TSHR (0.39) | TSHRALDH1A1SMN1; SMN2DNM1 | |
| SCHEMBL7075066 | 0.78 | TSHR (0.34) | TSHRALDH1A1DNM1 | |
| SCHEMBL8946847 | 0.75 | TSHR (0.43) | TSHRALDH1A1DNM1 | |
| SCHEMBL7040570 | 0.75 | TSHR (0.32) | TSHRALDH1A1DNM1 | |
| SCHEMBL7077244 | 0.75 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL7075538 | 0.75 | TSHR (0.32) | TSHRALDH1A1DNM1 | |
| SCHEMBL11049161 | 0.75 | TSHR (0.32) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL1082593 | 0.72 | FDPS (0.33) | TSHRALDH1A1 | |
| SCHEMBL7027674 | 0.72 | TSHR (0.32) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266742-A1 | Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease | HORIZON TECHNOLOGY FUNDING COMPANY, LLC | 2004-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266742-A1 | Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease | SOD1, MPO, SOD3 | TSHR 3223/4885ALDH1A1 750/4885SMN1; SMN2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.